Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241449 · ClinicalTrials.gov registry record · Phase 3
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT00241449 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 51 participants.
The verdict
NCT00241449, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.
Interventions
- DRUG Tamoxifen
- DRUG Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 1998-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241449
The ClinicalTrials.gov registry entry for NCT00241449 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT00241449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241449 about?
NCT00241449 is a clinical study titled "A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer". The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in th...
What is the current status of trial NCT00241449?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 1998-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00241449?
The interventions under investigation include: Tamoxifen (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT00241449?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.